PRNewsWire
31 May 2026, 23:30 UTC · 2h ago
Source · https://www.prnewswire.com/news-releases/tiumbio-to-present-phase-2a-interim-data-highlighting-differentiated-clinical-profile-for-tosposertibtu2218-plus-pembrolizumab-in-first-line-rm-hnscc-at-asco-2026-302786558.html
Read source
Story key points
4 claims · impact-rated
TiumBio's Phase 2a trial of Tosposertib plus Pembrolizumab in first-line R/M HNSCC showed a 75% response rate and a median progression-free survival (mPFS) of 10.9 months. — Strong efficacy data in a first-line setting, which the company claims compares favorably to current standard-of-care, is a primary driver for biotech valuation.
+0.80In second-line or later treatment settings, the Tosposertib combination achieved a 42.9% response rate, significantly higher than the historical 10-15% range. — Demonstrating efficacy in refractory/later-line patients expands the potential addressable market and utility of the drug.
+0.60TiumBio intends to explore regulatory pathways, including seeking Breakthrough Therapy Designation, based on these interim results. — Accelerated regulatory pathways can significantly shorten the time to market and increase the net present value of the asset.
+0.40Continue reading
6 related stories
Search tags
The combination therapy showed a Grade 3 or higher treatment-related adverse event (TRAE) incidence of 48.3%, with no Grade 5 events or cardiovascular toxicities reported. — A high rate of Grade 3+ events is a risk, but the absence of deaths or cardiovascular toxicity suggests a manageable safety profile.
+0.20Ticker attribution
Model heads
The company reported positive Phase 2a interim data for Tosposertib, showing favorable response rates and progression-free survival in HNSCC patients.
The company's drug Keytruda was part of a successful combination therapy showing positive clinical outcomes.
Impact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
PRNewsWire
1h ago
